In addition, treatment with enzalutamide (ENZ) and ARV-110, two anti-AR drugs, enhance the sensitivity of AR+ prostate cancer cells to ferroptosis by decreasing the expression of MBOAT2 [91]. The gene discussed is AR; the disease is prostate carcinoma.